drug for tuberculosis.
raw materials from CSC and sold them to Zoja, who used them to manufacture
refused as it wanted to integrate vertically downmarket.
regards production of raw material and therefore able to control supply to
manufacturers of derivatives cannot, just because it decides to start
manufacturing these derivatives (in competition with its former customers) act
in such a way as to eliminate their competition.
dominant firm will benefit consumers but harm competitors, and that if ECJ is
forced to chose it will chose latter.]